Institute of Health Informatics, University College London, 222 Euston Road, London NW1 2DA, UK.
Clinical Effectiveness Group, Queen Mary University of London, Yvonne Carter Building, 58 Turner Street, London E1 2AB, UK.
J Antimicrob Chemother. 2024 Jan 3;79(1):134-142. doi: 10.1093/jac/dkad357.
To investigate the risk of adverse outcomes following discordant antibiotic treatment (urinary organism resistant) for culture-confirmed community-onset lower urinary tract infection (UTI).
Cohort study using routinely collected linked primary care, secondary care and microbiology data from patients with culture-confirmed community-onset lower UTI (COLUTI). Antibiotic treatment within ±3 days was considered concordant if the urinary organism was sensitive and discordant if resistant.The primary outcome was the proportion of patients experiencing urinary infection-related hospital admission (UHA) within 30 days. Secondary outcomes were the proportion of patients experiencing reconsultation within 30 days, and the odds of UHA and reconsultation following discordant treatment, adjusting for sex, age, risk factors for complicated UTI, previous antibiotic treatment, recurrent UTI and comorbidities.
A total of 11 963 UTI episodes in 8324 patients were included, and 1686 episodes (14.1%, 95% CI 13.5%-14.7%) were discordant. UHA occurred in 212/10 277 concordant episodes (2.1%, 95% CI 1.8%-2.4%) and 88/1686 discordant episodes (5.2%, 95% CI 4.2%-6.4%). Reconsultation occurred in 3961 concordant (38.5%, 95% CI 37.6%-39.5%) and 1472 discordant episodes (87.3%, 95% CI 85.6%-88.8%). Discordant treatment compared with concordant was associated with increased odds of UHA (adjusted OR 2.31, 95% CI 1.77-3.0, P < 0.001) and reconsultation (adjusted OR 11.25, 95% CI 9.66-13.11, P < 0.001) on multivariable analysis. Chronic kidney disease and diabetes mellitus were also independently associated with increased odds of UHA.
One in seven COLUTI episodes in primary care were treated with discordant antibiotics. In higher risk patients requiring urine culture, empirical antibiotic choice optimization could meaningfully reduce adverse outcomes.
研究对培养证实的社区获得性下尿路感染(UTI)患者采用不一致的抗生素治疗(尿培养的病原体耐药)后发生不良结局的风险。
这是一项使用常规收集的初级保健、二级保健和微生物学数据的队列研究,纳入了培养证实的社区获得性下尿路感染(COLUTI)患者。如果尿培养的病原体敏感,则在 3 天内使用的抗生素治疗被认为是一致的,而如果尿培养的病原体耐药则为不一致的。主要结局是在 30 天内发生尿路感染相关住院治疗(UHA)的患者比例。次要结局是在 30 天内再次就诊的患者比例,以及在接受不一致治疗后发生 UHA 和再次就诊的可能性,调整了性别、年龄、复杂性尿路感染的危险因素、既往抗生素治疗、复发性 UTI 和合并症。
共纳入了 8324 例患者的 11963 次 UTI 发作,其中 1686 次发作(14.1%,95%CI 13.5%-14.7%)为不一致。在 10277 次一致治疗的发作中有 212 次(2.1%,95%CI 1.8%-2.4%)发生 UHA,而在 1686 次不一致治疗的发作中有 88 次(5.2%,95%CI 4.2%-6.4%)。在 3961 次一致治疗的发作中有 3961 次(38.5%,95%CI 37.6%-39.5%)和 1472 次(87.3%,95%CI 85.6%-88.8%)再次就诊。多变量分析显示,与一致治疗相比,不一致治疗与 UHA 的发生几率增加相关(调整后的比值比 2.31,95%CI 1.77-3.0,P<0.001)和再次就诊的几率增加相关(调整后的比值比 11.25,95%CI 9.66-13.11,P<0.001)。慢性肾脏病和糖尿病也与 UHA 的发生几率增加独立相关。
初级保健中每七例 COLUTI 发作中有一例接受了不一致的抗生素治疗。在需要尿液培养的高危患者中,经验性抗生素选择优化可能会显著降低不良结局的发生。